Alpine Immune Sciences To Present Data From RUBY-1, A Phase 1 Study Of Povetacicept, At Upcoming Scientific Congresses On May 20 And Jun. 1
Portfolio Pulse from Benzinga Newsdesk
Alpine Immune Sciences will present data from its RUBY-1 Phase 1 study of Povetacicept at upcoming scientific congresses on May 20 and June 1.
May 19, 2023 | 8:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alpine Immune Sciences' presentation of RUBY-1 Phase 1 study data on Povetacicept may impact its stock price.
Alpine Immune Sciences' presentation of the RUBY-1 Phase 1 study data on Povetacicept at upcoming scientific congresses may generate interest and positive sentiment among investors, potentially leading to an increase in the stock price of the company.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100